Restoring splicing defects by antisense oligonucleotide therapy

被引：0
|
作者：
Collin, R. W. [1 ]
机构：
[1] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands
来源：
EUROPEAN JOURNAL OF HUMAN GENETICS | 2019年 / 27卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
S03.3
引用
收藏
页码：1050 / 1051
页数：2
相关论文
共 50 条
  • [41] Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression
    Kian Huat Lim
    Zhou Han
    Hyun Yong Jeon
    Jacob Kach
    Enxuan Jing
    Sebastien Weyn-Vanhentenryck
    Mikaela Downs
    Anna Corrionero
    Raymond Oh
    Juergen Scharner
    Aditya Venkatesh
    Sophina Ji
    Gene Liau
    Barry Ticho
    Huw Nash
    Isabel Aznarez
    Nature Communications, 11
  • [42] Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression
    Lim, Kian Huat
    Han, Zhou
    Jeon, Hyun Yong
    Kach, Jacob
    Jing, Enxuan
    Weyn-Vanhentenryck, Sebastien
    Downs, Mikaela
    Corrionero, Anna
    Oh, Raymond
    Scharner, Juergen
    Venkatesh, Aditya
    Ji, Sophina
    Liau, Gene
    Ticho, Barry
    Nash, Huw
    Aznarez, Isabel
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [43] Antisense oligonucleotide-based restoration of ABCA4 splicing defects caused by deep-intronic mutations associated with Stargardt disease
    Garanto, Alex
    Sangermano, Riccardo
    Albert, Silvia
    Khan, Mubeen
    Bauwens, Miriam
    Naessens, Sarah
    Allikmets, Rando
    Born, Ingeborgh
    Hoyng, Carel C. B.
    De Baere, Elfride
    Cremers, Frans P.
    Collin, Rob W. J.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [44] ANTISENSE THERAPY CORRECTS ABERRANT PTS-SPLICING
    Brasil, S.
    Viecelli, H. M.
    Desviat, L. R.
    Thoeny, B.
    Ugarte, M.
    Perez, B.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2011, 34 : S105 - S105
  • [45] Reviewing antisense oligonucleotide therapy, part 1 - Action and design
    Das, SK
    Miller, KJ
    BIOPHARM-THE APPLIED TECHNOLOGIES OF BIOPHARMACEUTICAL DEVELOPMENT, 1999, 12 (10): : 42 - +
  • [46] Fetal antisense oligonucleotide therapy for congenital deafness and vestibular dysfunction
    Wang, Lingyan
    Kempton, J. Beth
    Jiang, Han
    Jodelka, Francine M.
    Brigande, Alev M.
    Dumont, Rachel A.
    Rigo, Frank
    Lentz, Jennifer J.
    Hastings, Michelle L.
    Brigande, John, V
    NUCLEIC ACIDS RESEARCH, 2020, 48 (09) : 5065 - 5080
  • [47] Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases
    Verma, Ashok
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2018, 21 (01) : 3 - 8
  • [48] Reviewing antisense oligonucleotide therapy: part 2, delivery issues
    Das, SK
    Miller, KJ
    BIOPHARM-THE APPLIED TECHNOLOGIES OF BIOPHARMACEUTICAL DEVELOPMENT, 1999, 12 (11): : 44 - +
  • [49] Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic
    Rook, Morgan E.
    Southwell, Amber L.
    BIODRUGS, 2022, 36 (02) : 105 - 119
  • [50] Carbohydrate modifications in antisense oligonucleotide therapy: New kids on the block
    Manoharan, M
    Kawasaki, AM
    Prakash, TP
    Fraser, AS
    Prhavc, M
    Inamati, GB
    Casper, MD
    Cook, PD
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 1999, 18 (6-7): : 1737 - 1746
12345